A211 INCREASED RATES OF PPI DEPRESCRIPTION OVER TIME IN PATIENTS WITH UPPER GI BLEEDS
K Kecskemeti, M Borgaonkar, J Mcgrath

TL;DR
This study found that more patients stopped or reduced proton pump inhibitors after upper GI bleeds in recent years compared to earlier periods.
Contribution
The study demonstrates a significant increase in PPI deprescription rates over time in patients with upper GI bleeds.
Findings
PPI deprescription rates increased from 2% in 2015-2018 to 16% in 2019-2022.
The difference in deprescription rates between the two time periods was statistically significant (p < 0.001).
Abstract
Proton Pump Inhibitors (PPIs) are commonly used for various indications, including prophylaxis of upper GI bleeding. We aimed to assess if there has been more PPI deprescription in recent years in patients treated for Upper GI Bleeds (UGIB). Our study aimed to assess the frequency of PPI deprescription in patients treated with endoscopic therapy for UGIBs. We hypothesized that there was a higher rate of PPI deprescription in recent years. This retrospective cohort study analyzed patients who received endoscopic treatment for UGIB between the years 2015-2022. All patients who were treated with endoscopic therapy for an UGIB from two academic GI practices were included. PPI deprescription was defined as a 50% dose reduction, frequency reduction or complete medication discontinuation in the past 3 months or longer in established PPI users. To assess trends, the cohort was divided into…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAbdominal vascular conditions and treatments
